Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Cellular Biomedicine Group, Inc is a biotechnology business based in the US. Cellular Biomedicine Group shares (CBMG) are listed on the NASDAQ and all prices are listed in US Dollars. Cellular Biomedicine Group employs 217 staff and has a trailing 12-month revenue of around USD$322,950.
|Latest market close||USD$18.5|
|52-week range||USD$11.48 - USD$19.27|
|50-day moving average||USD$18.1841|
|200-day moving average||USD$17.0699|
|Wall St. target price||USD$19|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-2.315|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-07)||2.15%|
|1 month (2020-12-17)||-0.27%|
|3 months (2020-10-15)||0.43%|
|6 months (2020-07-15)||13.08%|
|1 year (2020-01-15)||5.71%|
|2 years (2019-01-15)||2.66%|
|3 years (2018-01-13)||N/A|
|5 years (2016-01-15)||50.41%|
|Gross profit TTM||USD$277,542|
|Return on assets TTM||-34.66%|
|Return on equity TTM||-129.91%|
|Market capitalisation||USD$353.4 million|
TTM: trailing 12 months
There are currently 266,556 Cellular Biomedicine Group shares held short by investors – that's known as Cellular Biomedicine Group's "short interest". This figure is 23.1% down from 346,566 last month.
There are a few different ways that this level of interest in shorting Cellular Biomedicine Group shares can be evaluated.
Cellular Biomedicine Group's "short interest ratio" (SIR) is the quantity of Cellular Biomedicine Group shares currently shorted divided by the average quantity of Cellular Biomedicine Group shares traded daily (recently around 32786.715867159). Cellular Biomedicine Group's SIR currently stands at 8.13. In other words for every 100,000 Cellular Biomedicine Group shares traded daily on the market, roughly 8130 shares are currently held short.
However Cellular Biomedicine Group's short interest can also be evaluated against the total number of Cellular Biomedicine Group shares, or, against the total number of tradable Cellular Biomedicine Group shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Cellular Biomedicine Group's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Cellular Biomedicine Group shares in existence, roughly 10 shares are currently held short) or 0.018% of the tradable shares (for every 100,000 tradable Cellular Biomedicine Group shares, roughly 18 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Cellular Biomedicine Group.
Find out more about how you can short Cellular Biomedicine Group stock.
We're not expecting Cellular Biomedicine Group to pay a dividend over the next 12 months.
Cellular Biomedicine Group's shares were split on a 1:100 basis on 31 January 2013. So if you had owned 100 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cellular Biomedicine Group shares – just the quantity. However, indirectly, the new 9900% higher share price could have impacted the market appetite for Cellular Biomedicine Group shares which in turn could have impacted Cellular Biomedicine Group's share price.
Over the last 12 months, Cellular Biomedicine Group's shares have ranged in value from as little as $11.48 up to $19.27. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cellular Biomedicine Group's is 1.3738. This would suggest that Cellular Biomedicine Group's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Cellular Biomedicine Group, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer and stem cell therapies for degenerative diseases in Greater China. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for treating a range of cancer indications comprising technologies in chimeric antigen receptor modified T cells (CAR-T), T-cells with genetically modified, tumor antigen-specific T-cell receptors, and next generation neoantigen-reactive bio-markers based tumor infiltrating lymphocytes; and human adipose-derived mesenchymal progenitor cells for the treatment of joint diseases The company's CAR-T products include CD20 for use in anti-tumor activities; CD22, a surface maker highly expressed in B cell malignancies in hairy cell leukemia; and B-cell maturation antigen therapies for treating refractory multiple myeloma in patients. It also develops NKG2D CAR therapies for use in NK cell signaling; alpha fetoprotein TCR-T therapies for treating hepatocellular carcinoma; tumor infiltrating lymphocyte therapies for treating immunogenic cancers; and knee osteoarthritis therapies, including AlloJoin therapy, which is in a Phase II clinical trial, as well as Re-Join that has completed the Phase IIb clinical trial. In addition, it engages in biopharmaceutical businesses, including research and development, technical support, technical service, and technology transfer activities in biomedical technology field; manufacturing non-food, pharmaceutical polypeptides, and medical devices; and the wholesale of cosmetics, sanitary products, and biological agents. The company has a collaboration agreement with Novartis Pharma AG to manufacture and supply their CAR-T cell therapy Kymriah in China. Cellular Biomedicine Group, Inc. was incorporated in 2001 and is headquartered in New York, New York.
Everything we know about the Home Point Capital Inc IPO, plus information on how to buy in.
Everything we know about the ALFI INC IPO, plus information on how to buy in.
Steps to owning and managing CDAY, with 24-hour and historical pricing before you buy.
Steps to owning and managing CPF, with 24-hour and historical pricing before you buy.
Steps to owning and managing CFFI, with 24-hour and historical pricing before you buy.
Steps to owning and managing BPY, with 24-hour and historical pricing before you buy.
Steps to owning and managing BANF, with 24-hour and historical pricing before you buy.
Steps to owning and managing AVDL, with 24-hour and historical pricing before you buy.
Steps to owning and managing TEAM, with 24-hour and historical pricing before you buy.
Steps to owning and managing AUDC, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.